-
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 Apr 2024 11:56 GMT
… license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi … claims more lives globally than cancer, chronic lung disease and diabetes …
-
The Interview: Biotech Leader and Alnylam CEO Yvonne Greenstreet
30 Jan 2024 18:16 GMT
… the Cambridge-based pharmaceutical company Alnylam, Greenstreet oversees a team currently … and Pfizer, ultimately joining Alnylam in 2016 before assuming the … targeted therapies and immunotherapies for cancer; the development of highly effective …
-
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
13 Dec 2023 12:49 GMT
… leading cause of cancer death worldwide.1 Alnylam announces today that … genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
Cervical Cancer Drugs Market Top Growth Companies, Global Growth, Size, Trends, Industry Analysis, Key Players by 2032
23 Nov 2023 11:55 GMT
… elements.
Regional manufacturing: Cervical Cancer Drugs Market provides detailed …
Pfizer, Inc.
Biocon Limited
Alnylam Pharmaceuticals, Inc.
Bristol-Myers … Latest Healthcare Reports:
Cervical Cancer Drugs Market
RNA Sequencing …
-
The Petri Dish: Concerns mar Verve data; Alnylam-Roche drug shows promise
16 Nov 2023 11:18 GMT
… backed Incendia Therapeutics, a cancer startup that rebranded from … drug that Roche AG promised Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY … meeting over the weekend, Alnylam revealed that the drug, … to the drug, Alnylam said.)
Alnylam plans to share additional …
-
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
03 Nov 2023 11:00 GMT
… C5 antibody) in combination with Alnylam Pharmaceuticals, Inc.’s cemdisiran … AM
*In collaboration with Alnylam Pharmaceuticals, Inc.
**In collaboration with … , allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, …
-
Want a biotech buyout? Target cancer
10 Oct 2023 18:21 GMT
… liquid biopsy for lung cancer
Liquid biopsy player Delfi … will play in cancer screening.
Read more.
Alnylam’s Onpattro rejected … a drug made by Alnylam Pharmaceuticals to treat the … leads to heart failure. Alnylam is currently developing an updated …
-
Cervical Cancer Drugs Market Size, Share And Comprehensive Analysis For 2023-2032
28 Sep 2023 15:30 GMT
… Alnylam Pharmaceuticals, and Allergan PLC.
Learn More On The Cervical Cancer … action effectively.
Cervical Cancer Drugs Market Segments
• By Cancer Type: Squamous … Cell Cancer, Adenocarcinoma
• By Drug …
-
FDA Action Alert: Amgen, Alnylam and BMS
02 Oct 2023 05:28 GMT
… types, including colorectal cancer and small cell lung cancer.
Alnylam Seeks Onpattro’s … its siRNA therapeutic Onpattro (patisiran).
Alnylam won its first approval for … neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma and renal cell …
-
Groundbreaking: First-in-Class Targeted MicroRNA Therapy Slows Cancer Tumor Growth
27 Sep 2023 15:46 GMT
… researchers attacks tumors by tricking cancer cells into absorbing a snippet … of reintroducing microRNA-34a to cancer cells appears simple, the research … researchers at the biotechnology company Alnylam used on similar short interfering …